WuXi Biologics and Inhibrx Enter an Exclusive Partnership for GMP Manufacturing
SHANGHAI, Sept. 11, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK, WuXi Bio), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Inhibrx, Inc. (Inhibrx), a biopharmaceutical company developing...
WuXi Biologics Selected into the Hang Seng HK 35 Index
HONG KONG, Aug. 29, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that the company has been selected by Hang Seng Indexes as a consti...
WuXi Biologics Reports Robust 2018 Interim Results
Revenue up 61.2% to a Record High of RMB1,054.4 Million Net Profit 270.7% of Same Period Last Year to RMB249.6 Million Diluted EPS 211.1% of Same Period Last Year *** Commenced Commercial Production of "Trogarzo™" Total Integrated Projects Increased to 187 Including 10 Late-Phase Projects Phe...
WuXi Biologics Commenced Process Validation in MFG2
* Produced 7 batches at 6,000L/12,000L bioreactor scale for three programs, the largest scale cell culture operations inChina at 100% success rate in MFG2, the largest biologics manufacturing facility globally leveraging single-use technology * Process validation in MFG2 is a key milestone of...
WuXi Biologics Announced Successful Completion of the First cGMP Run in MFG3
- One of the largest biologics clinical manufacturing facilities globally with 6 production lines which enable WuXi Biologics to complete 60 IND-enabling projects per year SHANGHAI, July 25, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK, WuXi Bio), a leading global open-access biologics te...
WuXi Biologics and Immune Pharmaceuticals Announce Late-Phase Development and Manufacturing Partnership for a First-In-Class Monoclonal Antibody
SHANGHAI and ENGLEWOOD CLIFFS, N.J., July 9, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Immune Pharmaceuticals (Nasdaq: IMNP) ("Immune")...
WuXi Biologics and Harbour BioMed Announce Strategic Development and Manufacturing Partnership
WuXi Biologics' first collaborative project based on novel fully human antibody platform - HCAb ("heavy chain only" antibodies) SHANGHAI and CAMBRIDGE, Mass., June 25, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-t...
WuXi Biologics Initiated Construction of a State-of-the-Art Integrated ADC Solution Center
WUXI, China, June 20, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced today that it has started the construction of a state-of-the-art ...
WuXi Biologics to Invest $60 Million to Establish a Biologics Production Facility in the United States
WORCESTER, Mass. and SHANGHAI, June 11, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it is to invest$60 million and hire ...
WuXi Biologics and Tsinghua University Innovation Center for Immune Therapy Sign MOU and Announce Strategic Partnership
BEIJING and SHANGHAI, May 29, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Tsinghua University Innovation Center for Immune Therapy (IC...
WuXi Biologics to Invest S$80 Million to Establish a Biologics Manufacturing Facility in Singapore
SINGAPORE and SHANGHAI, May 22, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it is to investS$80 million (equivalent to a...
WuXi Biologics and Bioasis Announce Initial Strategic Collaboration for the Development and Manufacturing of Bioasis' Lead Investigational Candidate to Treat Brain Cancer
Bioasis will draw on WuXi Biologics' expertise in developing complex biologic
molecules for production of xB3-001 to support analytical development,
formulation and IND-enabling in vivo studies
SHANGHAI and VANCOUVER, British Columbia, May 21, 2018 /PRNewswire/ -- WuXi
Biologics
WuXi Biologics to Build an Integrated Biologics Development, Clinical and Commercial Manufacturing Center in Shijiazhuang
BEIJING, China, May 16, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company, offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it is to build an integrated biologics development,...
WuXi Biologics to Invest €325 Million to Build Largest Biomanufacturing Facility Using Single-Use Bioreactors in Ireland
DUNDALK, Ireland and SHANGHAI, April 30, 2018 /PRNewswire/ -- An Taoiseach Leo Varadkar, Prime Minister of Ireland today announced that WuXi Biologics, a Hong Kong-listed (2269.HK) global open-access biologics technology platform company, is to invest €325 million and create 400 new jobs over fiv...
WuXi Biologics Wins CMO Leadership Award from Life Science Leader Magazine
SHANGHAI, April 16, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it had won CMO Leadership Award for Reliability at the 2...
WuXi Biologics to Install Industry's Largest Single-Use Bioreactor from ABEC at its New Commercial Manufacturing Facility
WUXI, China and BETHLEHEM, Pa., March 20, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it has selected 4,000 liter (L) Cu...
WuXi Biologics Reports Remarkable 2017 Annual Results: Revenue up 63.7% to a Record High of RMB1,618.8 Million
Revenue up 63.7% to a Record High of RMB1,618.8 Million Adjusted Net Profit up 85.1% to RMB408.1 Million Gross Profit Margin, Net Profit Margin and Adjusted Net Profit Margin All Increased Significantly Eight Late-Phase (Phase III) Projects Versus Three as of December 31, 2016 Total Integrated...
WuXi Biologics and Adagene Announce Strategic Development and Manufacturing Partnership
SHANGHAI, March 8, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Adagene Inc., an emerging biotech company discovering and developing in...
WuXi Biologics Receives Asia's CMO of 2017 from BioPharma Industry Awards
SHANGHAI, March 5, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it had receivedAsia's CMO of 2017 at the 8th Annual BioPh...
WuXi Biologics Announces Positive Profit Alert
SHANGHAI, March 5, 2018 /PRNewswire/ -- WuXi Biologics (Stock Code: 2269.HK), a leading global open-access biologics technology platform company that offers end-to-end solutions for biologics discovery, development and manufacturing, announced that based on the preliminary assessment of the unaud...
